A conserved dendritic-cell regulatory program limits antitumour immunity.
Animals
Antigens, Neoplasm
/ immunology
B7-H1 Antigen
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Carcinoma, Non-Small-Cell Lung
/ immunology
Dendritic Cells
/ drug effects
Humans
Immunotherapy
Interferon-gamma
/ immunology
Interleukin-12
/ immunology
Interleukin-4
/ antagonists & inhibitors
Lung Neoplasms
/ immunology
Male
Mice
Tumor Burden
/ drug effects
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
10
05
2019
accepted:
17
01
2020
entrez:
10
4
2020
pubmed:
10
4
2020
medline:
4
6
2020
Statut:
ppublish
Résumé
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control the response to checkpoint blockade in preclinical models and are associated with better overall survival in patients with cancer, reflecting the specialized ability of these cells to prime the responses of CD8
Identifiants
pubmed: 32269339
doi: 10.1038/s41586-020-2134-y
pii: 10.1038/s41586-020-2134-y
pmc: PMC7787191
mid: NIHMS1587324
doi:
Substances chimiques
Antigens, Neoplasm
0
B7-H1 Antigen
0
CD274 protein, human
0
Cd274 protein, mouse
0
Interleukin-12
187348-17-0
Interleukin-4
207137-56-2
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-262Subventions
Organisme : NIAID NIH HHS
ID : U19 AI128949
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA154947
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190400
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA212376
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI137244
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA078207
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI089824
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA243210
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Références
Sánchez-Paulete, A. R. et al. Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant Semliki Forest Virus-derived fosters dendritic cell-mediated T-cell cross-priming. Cancer Res. 78, 6643–6654 (2018).
doi: 10.1158/0008-5472.CAN-18-0933
Salmon, H. et al. Expansion and activation of CD103
doi: 10.1016/j.immuni.2016.03.012
Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638–652 (2014).
doi: 10.1016/j.ccell.2014.09.007
Lavin, Y. et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750–765 (2017).
pubmed: 5737939
pmcid: 5737939
Ginhoux, F. et al. The origin and development of nonlymphoid tissue CD103
doi: 10.1084/jem.20091756
Sathaliyawala, T. et al. Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity 33, 597–606 (2010).
doi: 10.1016/j.immuni.2010.09.012
Miller, J. C. et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 13, 888–899 (2012).
doi: 10.1038/ni.2370
Idoyaga, J. et al. Specialized role of migratory dendritic cells in peripheral tolerance induction. J. Clin. Invest. 123, 844–854 (2013).
pubmed: 23298832
pmcid: 3561796
Steinman, R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685–711 (2003).
doi: 10.1146/annurev.immunol.21.120601.141040
Ohl, L. et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21, 279–288 (2004).
doi: 10.1016/j.immuni.2004.06.014
Helft, J. et al. Cross-presenting CD103
doi: 10.1172/JCI60659
Delamarre, L., Pack, M., Chang, H., Mellman, I. & Trombetta, E. S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307, 1630–1634 (2005).
doi: 10.1126/science.1108003
Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity 49, 1148–1161 (2018).
doi: 10.1016/j.immuni.2018.09.024
Stitt, T. N. et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80, 661–670 (1995).
doi: 10.1016/0092-8674(95)90520-0
Rothlin, C. V., Carrera-Silva, E. A., Bosurgi, L. & Ghosh, S. TAM receptor signaling in immune homeostasis. Annu. Rev. Immunol. 33, 355–391 (2015).
doi: 10.1146/annurev-immunol-032414-112103
Skinner, H. D. et al. Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin. Cancer Res. 23, 2713–2722 (2017).
doi: 10.1158/1078-0432.CCR-16-2586
Tsukita, Y. et al. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas. Mol. Cancer 18, 24 (2019).
doi: 10.1186/s12943-019-0953-y
Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).
doi: 10.1016/j.cell.2016.02.065
Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286–291 (2013).
doi: 10.1126/science.1232227
Mantovani, A. & Allavena, P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 212, 435–445 (2015).
doi: 10.1084/jem.20150295
Zahner, S. P. et al. Conditional deletion of TGF-βR1 using Langerin-Cre mice results in Langerhans cell deficiency and reduced contact hypersensitivity. J. Immunol. 187, 5069–5076 (2011).
doi: 10.4049/jimmunol.1101880
Xue, W. et al. Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov. 1, 236–247 (2011).
doi: 10.1158/2159-8290.CD-11-0073
Stoeckius, M. et al. Simultaneous epitope and transcriptome measurement in single cells. Nat. Methods 14, 865–868 (2017).
doi: 10.1038/nmeth.4380
Stoeckius, M. et al. Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. Genome Biol. 19, 224 (2018).
doi: 10.1186/s13059-018-1603-1
Jaitin, D. A. et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 343, 776–779 (2014).
doi: 10.1126/science.1247651
Paul, F. et al. Transcriptional heterogeneity and lineage commitment in myeloid progenitors. Cell 163, 1663–1677 (2015).
doi: 10.1016/j.cell.2015.11.013
Baran, Y. et al. MetaCell: analysis of single cell RNA-seq data using K-nn graph partitions. Genome Biol. 20, 206 (2019).
doi: 10.1186/s13059-019-1812-2
Gubin, M. M. et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell 175, 1443 (2018).
doi: 10.1016/j.cell.2018.11.003
Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 24, 1277–1289 (2018).
doi: 10.1038/s41591-018-0096-5
Holland, S. J. et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70, 1544–1554 (2010).
doi: 10.1158/0008-5472.CAN-09-2997
Agudo, J. et al. GFP-specific CD8 T cells enable targeted cell depletion and visualization of T-cell interactions. Nat. Biotechnol. 33, 1287–1292 (2015).
doi: 10.1038/nbt.3386